Jan H. Beumer

Also affiliated with University of Pittsburgh, Johns Hopkins Medicine, UPMC Hillman Cancer Center, Sidney Kimmel Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 39 papers. Top paper: “A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer”.

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

Cancer Chemotherapy and Pharmacology(2022)10.1007/s00280-022-04430-6

N/A

0.560DataRank · unranked

10 citations

Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin, Leonard J. Appleman +30 more

Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)

Seminars in Oncology(2023)10.1053/j.seminoncol.2023.01.001

N/A

0.432DataRank · unranked

7 citations

David M. Zahrieh, Jun He, Blake Waechter, Julianne L. Holleran, Lionel D. Lewis +9 more

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

The Oncologist(2025)10.1093/oncolo/oyaf362

N/A

0.307DataRank · unranked

6 citations

Mark Jelinek, Arjun Singh, Brian R. Isett, Erica S. Myers, Steven J. Mullett +23 more

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

medRxiv(2025)10.1101/2025.07.19.25331848

N/A

0.279DataRank · unranked

5 citations

Mark Jelinek, Arjun Singh, Brian R. Isett, Erica S. Myers, Steven J. Mullett +23 more

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04778-5

N/A

0.258DataRank · unranked

4 citations

Shivaani Kummar, Larry Rubinstein, Deborah Wilsker, Nancy Young Moore, Murielle Hogu +16 more

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04840-2

N/A

0.241DataRank · unranked

4 citations

Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain, Changchuan Jiang, Julianne L. Holleran +11 more

Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)

The Oncologist(2025)10.1093/oncolo/oyaf373

N/A

0.109DataRank · unranked

1 citations

Benjamin Schluger, Hong Wang, James Ohr, Daniel P. Petro, Alexander D. Fuld +10 more

An LC–MS/MS method for determination of the bromodomain inhibitor ZEN-3694 and its metabolite ZEN-3791 in human plasma

Bioanalysis(2024)10.4155/bio-2023-0252

N/A

0.104DataRank · unranked

1 citations

Haider Mahdi, Richard Piekarz, Jan H. Beumer, Timothy W. Synold, Ye Feng

Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04509-8

N/A

0.104DataRank · unranked

1 citations

Benjamin C. Kennard, Julianne L. Holleran, Nancy Young Moore, Jennifer Zlott, Brian Miller +7 more

Modular Smart Molecules for PSMA-Targeted Chemotherapy

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-22-0160

N/A

0DataRank · unranked

17 citations

Michael Pun, Jacob W. Herman, Oscar Romero, Mitchell Maniatopoulos, Joseph D. Latoche +6 more

Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice

Cancer Chemotherapy and Pharmacology(2022)10.1007/s00280-022-04436-0

N/A

0DataRank · unranked

8 citations

Joshua J. Deppas, Jianxia Guo, Robert A. Parise, David A. Clump, Christopher J. Bakkenist +2 more

NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3012

N/A

0DataRank · unranked

13 citations

Karen Kelly, Saiama N. Waqar, Elizabeth J. Davis, Geoffrey I. Shapiro, Patricia LoRusso +7 more

A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3174

N/A

0DataRank · unranked

5 citations

Paul Frankel, Jan H. Beumer, Naoko Takebe, Ming Yin, Hamid Emamekhoo +4 more

Thymidine rescues ATR kinase inhibition induced deoxyuridine contamination in genomic DNA, cell death, and Type 1 interferon expression

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.02.24.481821

N/A

0DataRank · unranked

1 citations

Frank P. Vendetti, Andrew J. Cipriano, Pinakin Pandya, Joshua J. Deppas, Tatiana N. Moiseeva +12 more

Short-course but not prolonged treatment with ATR inhibitor AZD6738 integrates with radiotherapy to generate a tumor antigen-specific CD8 + T cell expansion in the periphery

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.04.11.487886

N/A

0DataRank · unranked

0 citations

D.A. Clump, Sandra Schamus-Haynes, Maria diMayorca, Naveed M. Islam, Jina Chang +3 more

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy

JCI Insight(2023)10.1172/jci.insight.165615

N/A

0DataRank · unranked

36 citations

Pinakin Pandya, David A. Clump, Sandra Schamus-Haynes, Meysam Tavakoli, Maria diMayorca +6 more

A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06889-0

N/A

0DataRank · unranked

8 citations

Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin +13 more

Murine toxicology and pharmacokinetics of lead next generation galeterone analog, VNPP433-3β

Steroids(2023)10.1016/j.steroids.2023.109184

N/A

0DataRank · unranked

9 citations

Retheesh S. Thankan, Puranik Purushottamachar, Jianxia Guo, Robert A. Parise, Jan H. Beumer +2 more

Tumor cell p38 inhibition to overcome immunotherapy resistance

Research Square(2023)10.21203/rs.3.rs-3183496/v1

N/A

0DataRank · unranked

5 citations

Rebekah Dadey, Ryan C. Augustin, Sarah Newman, Krishna B. Singh, Rose Doerfler +26 more

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3022

N/A

0DataRank · unranked

2 citations

Alice P. Chen, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Naoko Takebe +15 more

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

European Journal of Cancer(2024)10.1016/j.ejca.2024.114024

N/A

0DataRank · unranked

26 citations

Markus Joerger, Yung‐Jue Bang, Ron H.J. Mathijssen, Caicun Zhou, Li Zhang +6 more

Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients

Cancer Letters(2024)10.1016/j.canlet.2024.216679

N/A

0DataRank · unranked

5 citations

Jiyue Qin, Xiaonan Xue, S. Percy Ivy, Thomas D. Nolin, Jan H. Beumer +1 more

Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04675-3

N/A

0DataRank · unranked

4 citations

Brian F. Kiesel, Jianxia Guo, Robert A. Parise, David A. Clump, David Z. D’Argenio +3 more

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04651-x

N/A

0DataRank · unranked

1 citations

Naoko Takebe, Alice P. Chen, Shivaani Kummar, Richard Piekarz, Brian F. Kiesel +5 more

Deoxyuridine-rich cytoplasmic DNA antagonizes STING-dependent innate immune responses and sensitizes resistant tumors to anti-PD-L1 therapy

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.04.04.588079

N/A

0DataRank · unranked

1 citations

Frank P. Vendetti, Joseph El-Ghoubaira, Sudipta Pathak, Joshua J. Deppas, Reyna Jones +12 more

All-trans retinoic acid induces durable tumor immunity in IDH-mutant gliomas by rescuing transcriptional repression of the CRBP1-retinoic acid axis

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.04.09.588752

N/A

0DataRank · unranked

1 citations

Xiaoran Zhang, Anthony R. Cillo, Jonathan Sussman, Poorva Sandlesh, Antonio Corral Tarbay +25 more

Comparative in vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation

Toxicology and Applied Pharmacology(2025)10.1016/j.taap.2025.117375

N/A

0DataRank · unranked

4 citations

Brian F. Kiesel, Jianxia Guo, Lora H. Rigatti, Joseph D. Latoche, Anthony R. Green +7 more

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0305

N/A

0DataRank · unranked

1 citations

Nataliya V. Uboha, Naoko Takebe, Kit Tam, Philippe L. Bédard, Kari B. Wisinski +13 more

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04844-y

N/A

0DataRank · unranked

1 citations

Shivaani Kummar, Larry Rubinstein, Jennifer Zlott, Geraldine O’Sullivan Coyne, Vincent Chung +17 more

Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer

Translational research(2020)10.1016/j.trsl.2020.10.005

N/A

0DataRank · unranked

16 citations

Brendon D. Honick, Robin Frederick, Anuleka Elapavaluru, Sachin Velankar, Hima Makala +9 more

Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate Cancer

medRxiv(2025)10.1101/2025.04.22.25326208

N/A

0DataRank · unranked

1 citations

Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain, Changchuan Jiang, Julianne L. Holleran +10 more

Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors

Investigational New Drugs(2020)10.1007/s10637-020-00962-x

N/A

0DataRank · unranked

14 citations

Smitha Krishnamurthi, Joel Saltzman, Joseph A. Bokar, Panos Savvides, Neal J. Meropol +12 more

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04073-5

N/A

0DataRank · unranked

26 citations

Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer +18 more

Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04030-2

N/A

0DataRank · unranked

24 citations

Allison L. Brodsky, Joseph A. Sparano, Stephanie V. Blank, Mimi Kim, Dawn L. Hershman +6 more

A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5599

N/A

0DataRank · unranked

2 citations

Jason Kirk, John W. Davis, Saby George, Ellis Levine, Jan H. Beumer +4 more

Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants

The Lancet Oncology(2021)10.1016/s1470-2045(21)00377-6

N/A

0DataRank · unranked

44 citations

S. Percy Ivy, Jan H. Beumer, Thomas D. Nolin, Morgan A. Casal

Quantitation of Cabozantinib in Human Plasma by LC–MS/MS

Journal of Chromatographic Science(2021)10.1093/chromsci/bmab090

N/A

0DataRank · unranked

4 citations

Julianne L. Holleran, Robert A. Parise, Michelle A. Rudek, Jennifer A. Chan, Yujia Wen +4 more

Development and validation of an LC–MS/MS generic assay platform for small molecule drug bioanalysis

Journal of Pharmaceutical and Biomedical Analysis(2021)10.1016/j.jpba.2021.114185

N/A

0DataRank · unranked

7 citations

Joseph M. Covey, Melinda G. Hollingshead, Apurva K. Srivastava, Timothy W. Synold, Jan H. Beumer +1 more

Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression

Cell Reports(2022)10.1016/j.celrep.2022.111371

N/A

0DataRank · unranked

25 citations

Frank P. Vendetti, Andrew J. Cipriano, Pinakin Pandya, Joshua J. Deppas, Tatiana N. Moiseeva +12 more